Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT06331559 Recruiting - Clinical trials for Advanced Solid Tumors

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Start date: March 31, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter Phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0501 in participants with advanced solid tumors. The trial consists two parts, Part 1 for SIM0501 monotherapy and Part 2 for SIM0501 in combination with olaparib. In both parts, SIM0501 with/without olaparib will be administered until disease progression or the investigator determines that continuation of the study drug would not benefit, or there is intolerable toxicity, or the participant or legal representative voluntarily requests withdrawal, or the trial is terminated.

NCT ID: NCT06329206 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

Start date: March 15, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).

NCT ID: NCT06314373 Recruiting - Clinical trials for Advanced Solid Tumors

A Study for HSK39775 in Participants With Solid Tumors

Start date: March 7, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

NCT ID: NCT06311578 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Start date: April 8, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.

NCT ID: NCT06299839 Recruiting - Clinical trials for Advanced Solid Tumors

PAS-004 in Patients With Advanced Solid Tumors

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: - How well participants are able tolerate different doses of PAS-004, and - What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will continue on daily PAS-004 for up to 2 years, or until: - They decide to withdraw from the study, or - They experience unacceptable side effects, or - Their disease progresses, or another illness interferes with taking the study drug, or - The sponsors stops the study.

NCT ID: NCT06242691 Recruiting - Clinical trials for Advanced Solid Tumors

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Start date: March 26, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses

NCT ID: NCT06239155 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Start date: September 3, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent

NCT ID: NCT06238401 Not yet recruiting - Clinical trials for Advanced Solid Tumors

Study of ACR246 in Advanced Solid Tumors

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.

NCT ID: NCT06235983 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this study is to determine how much of LY3537982 gets into the bloodstream and how long it takes the body to eliminate it in Chinese participants. The safety, tolerability and preliminary efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in this study.

NCT ID: NCT06235541 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

Start date: February 2024
Phase: Phase 1
Study type: Interventional

This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced solid tumors, for who no standard therapy exists, or standard therapy has failed.